Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 5. Pharmacological blockade of T-type calcium channels prevents abnormally increased proliferation in VPA-treated NPCs. (A, B) MTT analysis was conducted 24 h after the pharmacological blockade of calcium channels using (A) NNC55-0396 and (B) mibefradil in VPA-pretreated NPCs. NNC55-0396 and mibefradil treatment prevented an increase in the proliferation of VPA-treated NPCs [(A): N=4-8, one-way ANOVA followed by Tukey’s multiple comparison test, F(4, 27)=28.7, p<0.0001, (B): N=4, one-way ANOVA followed by Tukey’s multiple comparison test, F(4, 15)=15.64, p<0.0001]. (C) Levels of Pax6 protein were measured through western blotting 24 h after NNC55-0396 treatment in VPA-pretreated NPCs. NNC55-0396 did not block an increase in Pax6 levels in VPA-treated cells at 0.6 and 1.2 µM (N=3-4, one-way ANOVA followed by Tukey’s multiple comparison test, F(3, 11)=6.074, p=0.0108). Data are presented as mean ± SEM. N=4-5, *p<0.05, **p<0.01, ***p<0.001 vs. vehicle, #p<0.05, ###p<0.001 vs. VPA-treated group.
Biomolecules & Therapeutics 2020;28:389~396 https://doi.org/10.4062/biomolther.2020.027
© Biomolecules & Therapeutics